Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a TDM-guided study of mebendazole in advanced gastrointestinal cancer or cancer of unknown origin
2017-004163-12Phase 2Completed
- Sponsor
- Repos Pharma
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mebendazole in gastrointestinal cancer, liver cancer, cancer of unknown primary (CUP) and 2 more, sponsored by Repos Pharma. Primary endpoint: Safety profile of Repos MBZ. Started Dec 2017; status: completed.
02
Drugs
mebendazole
03
Conditions
gastrointestinal cancerliver cancercancer of unknown primary (CUP)squamous cell carcinoma (SCC)Adenocarcinoma
Beyond the preview
Go deeper on 2017-004163-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004163-12.